Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain
NCT02192190 · Eli Lilly and Company · PHASE2 · terminated · last registry update 2019-09-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Interim assessment: Lack of efficacy” | – | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-08-28Phase 3 first posted: Teva Branded Pharmaceutical Products R&D LLC, Fremanezumab (NCT04530110)
- 2020-08-24Results posted on the registry: Eli Lilly and Company, Galcanezumab (NCT02959190)
- 2020-07-09Phase 3 first posted: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT04464707)
- 2020-07-08Results posted on the registry: Eli Lilly and Company, Galcanezumab + Placebo (NCT03559257)
- 2020-07-07Phase 3 first posted: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT04458857)
- 2020-06-09Results posted on the registry: Alder Biopharmaceuticals, Inc., ALD403 (Eptinezumab) + Placebo (NCT02974153)
- 2020-06-05Phase 3 first posted: H. Lundbeck A/S, Eptinezumab + Placebo (NCT04418765)
- 2020-05-14Results posted on the registry: Alder Biopharmaceuticals, Inc., ALD403 + Placebo (NCT02559895)
- 2020-05-06Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab (NCT03107052)
- 2020-04-21Results posted on the registry: Alder Biopharmaceuticals, Inc., ALD403 (Eptinezumab) (NCT02985398)
- 2020-04-13Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT02945046)
- 2020-03-30Results posted on the registry: Alder Biopharmaceuticals, Inc., ALD403 + Placebo (NCT02275117)
- 2020-02-21Results posted on the registry: Eli Lilly and Company, Galcanezumab + Placebo (NCT02959177)
- 2020-01-09Results posted on the registry: Eli Lilly and Company, LY2951742 + Placebo (NCT01625988)
- 2019-11-05Phase 3 first posted: H. Lundbeck A/S, Eptinezumab + Placebo (NCT04152083)
- 2019-10-09Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT03308968)
- 2019-09-18Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT02964338)
- 2019-08-28Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT02638103)
- 2019-06-14Results posted on the registry: Eli Lilly and Company, LY2951742 + Placebo (NCT02104765)
- 2019-06-11Results posted on the registry: Eli Lilly and Company, Galcanezumab 300 mg + Placebo (NCT02438826)
- 2019-05-24Phase 3 first posted: Eli Lilly and Company, Galcanezumab + Placebo (NCT03963232)
- 2019-03-13Results posted on the registry: Eli Lilly and Company, Galcanezumab + Placebo (NCT02397473)
- 2019-03-13Results posted on the registry: Eli Lilly and Company, Galcanezumab (NCT02836613)
- 2019-02-26Results posted on the registry: Eli Lilly and Company, Galcanezumab + Placebo (NCT02576951)
- 2019-02-20Results posted on the registry: Eli Lilly and Company, LY2951742 + Placebo (NCT01337596)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision